Date: 2015-06-04
Type of information: Construction of new premises
Compound:
Company: Novozymes (Denmark)
Therapeutic area:
Type agreement: construction of new premises
Action mechanism:
Disease:
Details: * On June 4, 2015, Novozymes has signed a deal with Lyngby-Taarbæk Municipality to acquire a 140,000 square meter site in Lyngby. The site is located 13 kilometers north of Copenhagen, close to the highway to Elsinore and seven kilometers from its headquarters in Bagsværd. Novozymes’ goal is to build a new campus dedicated to research and business development. This new campus will be a hub for biotechnology. Approximately 14% of Novozymes’ revenue is reinvested into research annually, leading to the development of over 100 new products since the company went public 15 years ago. These products are used globally and enable energy-efficient production, replacement of fossil fuels, more sustainable food production and other benefits. As part of the campus construction, Novozymes will also establish a learning center where students and visitors alike are invited to discover and learn about the magic of nature and biology. The learning center will include teaching laboratories, a small cinema and a cafe, and will function as a link to the research environment in Lyngby. The site is 140,000 square meters. The first building phase consists of a 30,000 square meter construction, with room for 800 employees in research and development and other business areas. This first phase is expected to meet Novozymes\' space needs until the year 2023. Later expansion is possible, to room a total of 2,000 -2,500 employees. The inauguration of the new innovation campus is expected to take place in 2018 upon the approval of the district plan.
Financial terms:
Latest news:
